Efficacy of combination therapy with ezetimibe and statins versus a double dose of statin monotherapy in participants with hypercholesterolemia: a meta-analysis of literature

Table 1 Characteristics of the eligible studies

Study	Year	First Anthor	Country	Male	Age	Patients(n)		Therapy		follow-up	p value
				(%)	(Yrs)	E/S	D/S	EZE + Statin	Double Statin
1	2018	Hong SJ	Korea	63/70	63/63	65	65	EZE 10 mg + ROS 5 mg	ROS 10 mg	8 week	< 0.001
				59/62	62/64	66	64	EZE 10 mg + ROS 10 mg	ROS 20 mg	8 week	< 0.001
2	2017	Ran D	China	76/73	60/60	42	41	EZE 10 mg + ROS 10 mg	ROS 20 mg	12 week	< 0.001
3	2017	Sakamoto K	Japan	NR	NR	51	53	EZE 10 mg + ATO 10 mg/PIT 1 mg	ATO 20 mg/PIT 2 mg	52 week	0.0002
4	2017	Japaridze L	Georgia	54/53	62/62	141	135	EZE 10 mg + ATO 20 mg/40 mg	ATO 40 mg/80 mg	16 week	< 0.001
5	2016	Farnier M	France	54/69	60/61	48	48	EZE 10 mg + ROS 10 mg	ROS 20 mg	12 week	NR
				59/72	63/60	53	53	EZE 10 mg + ROS 20 mg	ROS 40 mg	12 week	NR
6	2015	Sakamoto K	Japan	57/59	63/62	45	48	EZE 10 mg + ATO 10 mg/PIT 1 mg	ATO 20 mg/PIT 2 mg	12 week	< 0.001
7	2015	Saeedi R	Canada	95/85	56/57	21	18	EZE 10 mg + ROS 10 mg	ROS 20 mg	12 week	0.37
8	2015	Le NA	American	NR	64/64	133	74	EZE 10 mg + SIM 20 mg	SIM 40 mg	12 week	<0.01
9	2013	Matsue Y	Japan	72/75	69/70	117	133	EZE 10 mg + ATO 10 mg	ATO 20 mg	12 week	< 0.001
10	2012	Okada K	Japan	73/74	65/65	78	72	EZE 10 mg + ATO 10 mg/ROS 2.5 mg	ATO 20 mg/ROS 5 mg	12 week	<0.01
				73/74	65/65	78	72	EZE 10 mg + ATO 10 mg/ROS 2.5 mg	ATO 20 mg/ROS 5 mg	52 week	<0.01
11	2010	Averna M	Italy	54/57	61/62	56	56	EZE 10 mg + SIM 20 mg	SIM 40 mg	6 week	< 0.001

Data reported as Ezetimibe+Statin/Double-dose Statin(E/S, D/S)
Abbreviations: EZE Ezetimibe, ROS Rosuvastatin, SIM Simvastatin, ATO Atorvastatin, PIT Pitavastatin, NR Not reported

ISSN: 1476-511X